Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View

Core Insights - Insmed (INSM) reported a fourth-quarter 2025 loss of $1.54 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $1.32 in the same quarter last year [1][10] - Quarterly revenues increased by 153% year over year to over $263.8 million, driven entirely by the sales of its two marketed products, aligning with the Zacks Consensus Estimate [1][10] Financial Performance - Insmed's total revenues for the full year 2025 reached $606.4 million, marking a 67% increase year over year [7] - The company reported a full-year loss of $6.42 per share, worsening from a loss of $5.57 in the previous year [7] Product Sales - Sales of Arikayce rose 14% year over year to $119.2 million, slightly exceeding the Zacks Consensus Estimate of $118.8 million, driven by increased demand across all regions [3] - Brinsupri, which was approved in August 2025, generated $144.6 million in sales during its first full quarter, significantly up from $28.1 million in the previous quarter and surpassing the Zacks Consensus Estimate of $128.6 million [4] Expenses - Research and development expenses increased by 42% year over year to $254.9 million, attributed to a rise in employee headcount and clinical expenses [5] - Selling, general and administrative expenses rose by 49% to $212.5 million, driven by higher professional service costs and increased compensation to support Brinsupri's commercial launch [6] 2026 Guidance - Insmed expects Arikayce product sales to be between $450 million and $470 million for 2026, indicating a 6% year-over-year growth at the midpoint [8] - The company anticipates Brinsupri sales to reach at least $1 billion, reflecting strong sales momentum [8] Pipeline Developments - Insmed has completed patient enrollment in the phase III ENCORE study for Arikayce, with top-line data expected in March or April 2026 [12] - Brinsupri has been approved in the EU for treating NCFB, with regulatory reviews ongoing in the UK and Japan [13] - The company is also advancing its investigational drug TPIP for pulmonary arterial hypertension and plans to initiate additional studies in 2026 [14]